Annual Report

Overview

The report describes OBI Pharma's 2016 progress toward a broader oncology portfolio, including clinical progress for OBI-822 and development of OBI-833, OBI-888 and OBI-999. It reports 120 employees in the 2016 column, 2016 net revenue of NT$ 92,422 thousand primarily from the DIFICID rights-transfer payment, and R&D costs of NT$ 859,480 thousand. The company also describes corporate social responsibility, laboratory safety, waste reduction, and energy-saving measures.

Document

Report type: Annual Report with Sustainability Disclosures
Class: Embedded
Scope: Full report
Period: 1 January 2016 – 31 December 2016
Publication date: 30 April 2017
Language: English
Pages
File size

Standards

Other

Materiality

Assessment
Basis

Assurance

Statement included

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services